Patients with high blood pressure in the lungs will keep access to YUTREPIA as Liquidia settles six lawsuits.
Liquidia (LQDA) and United Therapeutics (UTHR) settled six lawsuits, allowing uninterrupted access to YUTREPIA for pulmonary arterial hypertension. Liquidia will pay $380.7M in 2026-2027, with $222.7M in Q3 YUTREPIA sales and $396.1M in cash as of September 2026. Liquidia plans to continue developing YUTREPIA and L606.
How this was made
The 30-second read
Why it matters
The settlement removes legal uncertainty, but Liquidia faces a sizable cash outlay; United Therapeutics gains cash and eliminates litigation risk.
Market read
First disclosure of a $380 M settlement that resolves all pending litigation, impacting cash flow and stock outlook for both firms.
What to watch
Potential future collaborations between Liquidia and United Therapeutics could arise from the resolved disputes.
Background
Liquidia and United Therapeutics resolved six lawsuits, preserving YUTREPIA availability while Liquidia commits to a multi‑year payment schedule.
Ticker impact
Liquidia announced a $380.7 million settlement with United Therapeutics, payable in 2026‑27, preserving YUTREPIA access.
likely short‑term pressure as investors price the settlement payment
The settlement amount is material relative to Liquidia's cash position and will be funded from sales, creating near‑term cash‑flow concerns.
United Therapeutics will receive a $380.7 million settlement from Liquidia, ending all pending litigation.
likely upside as the market prices in the cash inflow
The settlement resolves antitrust and patent disputes and provides a sizable cash infusion.
Market effects
The PAH drug market sees continuity of YUTREPIA supply, reducing uncertainty for competitors.
US biotech sector may see modest volatility as settlement highlights litigation risk.
Limited to investors in the two companies and the pulmonary hypertension therapeutic space.
Counterpoint
The settlement may be viewed as a strategic move that clears legal hurdles, enabling stronger growth for both firms.
Key entities
- CompanyLiquidia Corporation
Biopharma developing inhaled treprostinil (YUTREPIA) and pipeline L606.
- CompanyUnited Therapeutics Corporation
Owner of the treprostinil patents involved in the litigation.
